Sinus Health - Presented by Sinofresh Healthcare

SinoFresh Nasal Spray For H1N1 (Swine Flu) Virus

2009-11-25T22:04:00.000-08:00

SinoFresh Nasal Spray Achieves Positive Results Against H1N1 (Swine Flu) Virus in Initial Pilot Animal Study

Test data suggests that nasal treatment with SinoFresh decreased the severity and/or incidence of H1N1 infection in test group animals.

VENICE, Fla., SinoFresh Healthcare Products, Inc. announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 ("swine flu") virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals. In addition, pre-treatment with SinoFresh Nasal Spray decreased the severity and/or incidence of infection.

Dr. Michael Stampar, D.O., Senior Medical Advisor to SinoFresh Healthcare Products, stated, "We are very encouraged by this initial study report and will continue to develop data to support our belief that SinoFresh Nasal Spray, a broad based antiseptic solution is an important component in protecting the health of patients that are exposed to the H1N1 ('swine flu') virus."

The study which was conducted by SRS International Corp of Falls Church VA. was conducted over 14 days and was designed to evaluate the severity of infection from H1N1 ("swine flu") virus in the Cotton Rat animal model, a well accepted model for studying human nasal and respiratory tract infection by viruses and other microbial pathogens. In this study, the test animals were inoculated with H1N1 and then received SinoFresh Nasal Spray in the nose three times daily for 14 days. The study evaluated the product's likelihood of efficacy in both prevention and treatment. One group of animals was treated with SinoFresh Nasal Spray prior to inoculation with H1N1 and a second group was treated starting 15 minutes after inoculation with H1N1 while the remaining "control group" received no treatment during the overall 14 day study period.

The Company has now also initiated a study to evaluate the product's ability to reduce or eliminate viral shedding which is the main method of transmission of the H1N1 flu virus. The active phase of the additional study has been completed and is in the laboratory for evaluation. Results are expected in the next few weeks. SinoFresh Healthcare Products, Inc. is a privately held exclusive marketer of innovative upper respiratory system therapies.

The Company uses broad-spectrum antiseptic approaches to reduce viral, bacterial, and fungal organisms that are suspected to cause pathogenesis of the mouth, nose, and throat. The Company's lead product, SinoFresh Nasal Spray, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. This product and a planned series of follow-on products built on the Company's proprietary technology will, in time, exploit an enormous global opportunity for the SinoFresh product line as people begin to understand the benefit of using a daily preventative antiseptic product that can actually address the causes of diseases in the upper respiratory area.

For more information please visit: www.sinofreshstore.com

THE TRAVLERS ADVANTAGE COMBATING TWO SILENT HAZARDS

2009-11-04T06:23:00.000-08:00

As a pilot for more than thirty years I have relied upon check lists for my safety and the safety of my passengers. About ten years ago, I modified my take off check list as follows:
DOORS CLOSED AND SECURE : CHECK
TAXI CLEARANCE : CHECK
TAKE OFF CLEARANCE : CHECK
CABIN PRESSURE SET : CHECK
SINOFRESH : CHECK!!

Let me explain:
For the duration of most commercial flights, passengers are confined to an environment that has been created for them, as well as being exposed to all the airborne viral and bacterial germs brought aboard the aircraft by the many passengers.

Pressurizing the aircraft is done to offset the effects of high altitude flight. Basically this means, there is not enough atmospheric pressure at high altitudes to allow the body to release CO2 and nitrogen gasses. In creating an atmosphere that can be tolerated by humans, the generated air is very hot and dry, (10% to 20% humidity) and must therefore be cooled prior to release into the cabin, though remaining very dry.

If you have ever wondered why flight attendants push the consumption of liquids during flights, now you know; so you can remain hydrated. What you may not know; The environment that has been created dries out the sensitive membranes in the upper airway where viruses take hold. If your nasal and sinus passages dry out, your body’s natural defense mechanism, (a moist healthy nose), is severely compromised.

Combating the second Silent Hazard, specifically, the quality of the air you breathe during flight has been controversial since the 60’s-era aircraft began to be phased out. With the newer turbofan jet engines, more air means better fuel efficiency. Drawing off air to circulate through the cabin makes the engines less efficient, thus burning more fuel and costing the airline more money. The greatest risk here is confined space and communicable diseases among the passengers. Many airlines have published glowing reports regarding pristine air quality, however most samples are taken at peak performance of the aircraft engines. In today’s crowded airspace the potential for ground delays are very common resulting in the conditioning system being less efficient. There can be little doubt what impact this has on your health. One researcher from the Centers for Disease Control and Prevention found that 72% of passengers on a particular jet that had experienced a lengthy delay on the ground caught the flu!!

What is the SinoFresh Travelers Advantage? First and foremost, as a pilot bound by very stringent FAA rules governing drug screening requirements, I do not have to be concerned about side effects such as downiness, impaired judgment, rebound dependency, and a host of other issues often encountered with the use of drugs, even many over the counter remedies. Beyond that important advantage, by using SinoFresh, I know I am helping my nose’s natural moistening process. A friend of mine, Dr. Michael Stampar, who is a Ear, Nose and Throat physician has often told me this is very important. And lastly, but of extreme importance is the ability SinoFresh has in killing germs and bacteria in the nose before they can bring harm to me and others whom I may be breathing on. Over the years I have developed the notion that cleansing my nose is as important as cleansing my hands in the personal prevention regimen I embrace to defend against upper respiratory diseases. I have also learned that the use of SinoFresh is no more intrusive than brushing my teeth and gargling with an antiseptic mouth wash.

By the way, we have all heard about the grammar school teacher who developed a certain product because “she was tired of being sick.” As an aircraft pilot, I invented and patented SinoFresh with a similar goal in mind utilizing my knowledge and understanding of airplane systems and traveler’s needs.

SinoFresh ™ Nasal and Sinus Care is in wide scale retail and internet distribution. Further information can be obtained by visiting www.sinofresh.blogspot.com or ordered at www.sinofreshstore.com

Spread of the H1N1 virus in the U.S. & other nations

2009-10-02T00:28:00.000-07:00

VENICE, FL, September 21, 2009 -- David R. Olund, President of SinoFresh Healthcare Products, Inc., says, "the company is initiating this preliminary study in response to widespread concern over the continued spread of the H1N1 virus in the U.S. and Internationally. SinoFresh's topical antiseptic nasal spray has demonstrated in previous studies the ability to reduce the presence of a wide range of airborne pathogens in the nasal and sinus cavities and we believe that the product may have a favorable effect on the H1N1 virus. Our goal is that the SinoFresh product line will ultimately emerge as a cost effective consumer and institutional option for broad based airborne disease prevention."

Chief Medical advisor, Dr. Michael Stampar says "Our goal is to demonstrate that a topical antiseptic nasal spray can prevent infection, reduce severity or reduce the duration of viral shedding. Previously positive in-vitro and in-vivo studies that included a number of widely known airborne pathogens, as well as MRSA, give the Company reason to be optimistic in my opinion."

SinoFresh HealthCare Products, Inc. is a privately held exclusive global marketer of innovative upper respiratory system therapies including its lead product, SinoFresh Homeopathic Nasal Spray, a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The Company uses broad-spectrum antiseptic approaches to reduce the load of viral, bacterial, and fungal organisms present in the sinus and nasal cavities that are believed to be the cause of sinusitis and other pathogenesis of the mouth, nose, and throat.

Website: sinofreshstore.com

What Germs Are you Taking Home?

2009-08-17T00:23:00.000-07:00

VIRAL PREVENTION - IS IT REALLY POSSIBLE???

There can be no doubt; we live in a world that is faced with the constant threat of viral and bacterial upper respiratory infections. The media is filled with alarming articles on swine flu, bird flu, MRSA and Norovirus, just to mention a few. Leading scientist are stating in unison, “It is no longer a matter of if a pandemic outbreak will occur, it is a now a matter of When while many other experts are saying, it is already happening!!

The nose and throat play a vital role in the infectious process since better than 99% of all airborne diseases gain access to your body via the mouth and nose. Consider as an example an airplane environment; No matter the high quality of air that is provided for airline passengers, if a person finds themselves sitting next to an influenza carrier and that person sneezes or coughs, thus atomizing viral germs into the space of others, there is a high probability that people in the near vicinity will come down with the flu.

World health organizations have little to offer in terms of prevention other than to emphasize washing hands often with antimicrobial soaps and lotions. During the recent out-break of H1N1 (swine flu) people were left to wonder; if you come into contact with a flu carrier in the way stated earlier, breathing the air someone has just sneezed or coughed into, what will clean hands do to protect you? If on the other hand you choose to wear a cumbersome face mask as the masses were recently seen doing, one that is not hermetically worn against your face, how much protection will you really have? Is it logical to cleanse your hands every time you touch something such as a door knob, hand rail, elevator button, drawer, paper money and coins, food service counter (I think you get the picture), just how many hand cleansings will it take in a day in order to protect yourself?

WHAT IF YOU COULD CLEANSE YOUR NOSE AND THROAT with an antimicrobial solution that has been formulated to be effective against both viral and bacterial germs and yet be pleasing and refreshing? Would not that be a more effective, less intrusive method of protection? Does this sound like some futuristic method that your children could look forward to? The fact is, the product is here now and is already in wide scale retail and internet distribution. The product is called SinoFresh Nasal and Sinus Care.

Further information can be obtained by visiting www.sinofreshstore.com

TODAY’S TRAVELERS, HOW SAFE ARE WE?

2009-08-17T00:21:00.000-07:00

TODAY’S TRAVELERS, HOW SAFE ARE WE?

“Driven by consumer concerns, health related issues are likely to become the single greatest factor in the decision making process governing cruise and airline travel”.
Charles Fust, 2009

The buy line for this article at first glance appears to strike fear, nevertheless, consider the recent outbreak of swine flu and the impact it is having upon travelers worldwide, especially the cruise and airline industry. Cruise ships have recently diverted from their itineraries, some choosing to not make port stops at all, airline passengers are screened before boarding with authorities looking for “flu like symptoms” and all the while, people become increasingly alarmed. During this period of heightened awareness, health officials are constantly reminding us, that other than the obvious, hand cleansing using antimicrobial/antiseptic lotions and soaps are the only basic precaution at our disposal.

Many now believe that the swine flu outbreak we are experiencing pales in comparison to what could happen as we approach the next flu season. If these predictions are accurate, how many consumers will feel comfortable in crowed travel oriented spaces, especially terminals, eateries, planes and cruise ships? Except for those whose jobs depend upon travel, it can be assumed leisure travel will be severely crippled.

Cleansing ones hands, while not completely fail safe, is touted by many medical authorities as an important means of prevention. This is based upon the fact, by touch; viral germs can be transferred from various surfaces such as door knobs, hand rails, currency, chairs, hand dryers, toilet levers and many other places to our hands.. Once our hands come into contact with these surfaces, as we then touch our nose and mouth, germs gain access to our own upper respiratory system..

What if it was possible to create an environment in our nose and throat that would be inhospitable to harmful germs? Wouldn’t this be a great adjunct to the concept of cleansing our hands? We have all accepted that prevention and killing germs is normal and routine in terms of health benefits for our mouth, teeth and gums, why would we not consider protecting our nose and throat?
Due to coughing and sneezing, we must also consider the aerated germs that invade our immediate space, specifically contaminating the air we breathe, are not going to be impeded in the least by cleansing our hands. Now that we can, administering an extra measure of protection directly at the body’s gateway, specifically our nose and throat, may represent one of the most significant breakthroughs imaginable.

While this may sound a little futuristic, there is a product now available that has been formulated to kill germs in the nose and deep throat. The product, SinoFresh Nasal and Sinus Care is in wide scale retail and internet distribution. Further information can be obtained by visiting www.sinofreshstore.com

An ounce of prevention that lasts for a month…

PRICING VERSES VALUE/RESULTS

2009-08-17T00:18:00.000-07:00

PRICING VERSES VALUE/RESULTS
BY: Charles Fust
Inventor and Founder, SinoFresh Laboratories, Inc.

I have been asked many times over the years, “Why does SinoFresh™ Nasal and Sinus Care cost so much?” My first response is always, “Compared to what?” While this may seem somewhat cliché, my answer is substantiated by years of observation and research, further tempered by my own personal experiences.

Consumers who suffer through debilitating chronic sinusitis (CS) symptoms several times in any given year have, up until now, had basically two choices: to either self medicate themselves or to visit their physician. The outcome, no matter their choice, has always resulted in treatment of their symptoms.

What value can be assessed in terms of possibly not having the chronic episode in the first place? In addition to the pain and suffering, would not the prevailing illness register terrible consequences in terms of lost wages, physician office visits, expensive Rx treatments and over-the-counter treatment which can result in two or three different therapies often times necessary to deal with more than one symptom?

In 2000, Mayo Clinic announced in the Wall Street Journal they had concluded an exhaustive study of CS sufferers which resulted in discovery, for the first time, the triggering mechanism responsible for typical CS episodes. The article and a patent Mayo was awarded clearly identified numerous strains of mold and fungus as the culprit. In simple lay terms the Mayo findings were stated: As the nose filters and the sinuses condition the air we breathe, mold and fungus becomes trapped. In many individuals, this triggers an immune system response as their body fights to rid itself of the cumulative burden. As the immune system response intensifies, symptoms begin to appear such as watery eyes; headaches; and dry, stuffy and inflamed noses leading to swollen nasal and sinus tissues. Since mold and fungus are in such great abundance throughout the environment, often times exacerbated in warm, wet climates; trees; grass; air conditioning ducts; faulty plumbing; leaky buildings; and other fertile breeding habitats, CS episodes seem almost inescapable.

In 1996, SinoFresh™ began working with intra nasal applications of antiseptic and antifungal ingredients capable of killing exactly the types of mold and fungus described in the Mayo study. For its efforts, SinoFresh™ was rewarded with a patent portfolio numbering more than 100 patents worldwide and in 2000, began to commercialize the product SinoFresh™ Nasal and Sinus Care. This product, while pleasing and refreshing to use, has ingredients designed to kill mold and fungus in the nasal passage, before the pathogens can bring harm. A disruptive technology has evolved that is revolutionizing contemporary views on CS.

This all brings me back to the cost versus value/results question. The price of any pharmaceutical product can not be measured solely in terms of production cost or by comparison to a product that is less expensive, entirely different and possibly inferior. One has to consider the enormous price that must be paid for scientific evaluations, studies, research, patents, marketing, promotion and a host of other expenses all of which are directly related to the complexities encompassing retail cost. New technology creates an even greater cost burden due to the enormous expenses associated with consumer education and brand awareness. Obviously if the technology did not exist prior to the invention, consumers and the medical community have to be informed.

Over the years, many of the tens of thousands of satisfied SinoFresh customers have said to me: personally, “I don’t care what the product costs, just don’t stop making it!” Like me, they are experiencing happier, more productive life styles free of the pain and suffering associated with CS and like me, agree, pricing pales in comparison to results when viewed from a proper perspective.

SinoFresh ™ Nasal and Sinus Care is in wide scale retail and internet distribution. Further information can be obtained by visiting
www.sinofreshstore.com

An ounce of prevention that lasts for a month…

Senator Alquist's “Superbug” Legislation Passes the Senate Floor

2008-09-10T04:02:00.000-07:00

Legislation will establish MRSA screening, tracking, and prevention

SACRAMENTO— Legislation by Senator Elaine Alquist (D – San Jose) to help prevent the spread of the “superbug” known as MRSA and other hospital acquired infections passed the Senate on a 30-9 bipartisan vote.

“I am very pleased that the Senate recognized the value of addressing the MRSA and hospital acquired infection public health epidemic,” stated Alquist. “Hospitals and patients need to know where infection hot spots are so that we can protect against potentially dangerous situations.”

A bacterial infection resistant to most common antibiotics, MRSA (methicillin-resistant Staphylococcus aureas) can often look like an infected bug bite or scratch but left untreated, it can turn deadly or severely debilitating resulting in paralysis. In many cases, recovery can take several months and require IV antibiotics.
Senator Alquist’s legislation, SB 1058, has six major components:

* Infection Control Procedures – Requiring hospitals to implement procedures for identifying patients who are infected with MRSA such as detecting MRSA hotspots inside a hospital such as an ICU;

* Screening – Requiring hospitals to screen high-risk patients upon admission for MRSA so that other patients are protected;

* Enhanced Infection Prevention Protocols -- Requiring hospitals to follow enhanced protocols to protect against the spread of MRSA and other hospital acquired infections such as cleaning and disinfecting, among other items, all televisions, telephones, bedding, elevators, meeting rooms, glucometers, gurneys, feeding pumps, and cardiac monitors;

* Reporting – Requiring hospitals to report MRSA and other infection data to the state Department of Public Health (DPH);

* Public Disclosure – Requiring DPH, by 2011, to begin publishing infection data on its website; and

* Infection Control Staffing – Requiring hospitals to employ one infection control professional for every 100 licensed beds.

“People who go to the hospital should be safe from the threat of infection and today they are not,” Alquist added.
Hospital acquired infections have increased dramatically in recent years. Since the mid-1970s, there has been a 30-fold increase in MRSA in our hospitals. Staph-related deaths nationally, once a rarity, are approaching 20,000 annually, more than the number of AIDS deaths every year, and this number grows every year. Some 95,000 cases of serious MRSA infections are reported annually.

The Center for Disease Control (CDC) estimates that every year two million patients contract a hospital acquired infection while being treated for something else, and almost 100,000 die every year from these infections.Visit Senators site

Click to buy sinofresh products from its own store
www.sinofreshstore.com.

[video] Charles Fust, CEO of SinoFresh HealthCare Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.net's 3-Minute Press Show

2008-08-29T17:21:00.000-07:00

VENICE, Fla., Aug. 21 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc. (OTC Bulletin Board: SFSH - News), a developer and marketer of innovative upper respiratory system therapies, today announced that the company's CEO, Charles Fust, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show.The interview gives viewers an overview of the company, and the significance of the company's latest press release.

To view the clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Charles-Fust-SFSH/215/902
About SinoFresh HealthCare, Inc:

SinoFresh HealthCare, Inc. (OTC BB: SFSH.OB - News) is a developer and marketer of innovative upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh® Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh® products are available in major retail outlets nationwide. More information is available at http://www.sinofreshstore.com/

StockGuru.com Announces a New Executive Interview With Charles A. Fust of SinoFresh Healthcare Inc

2008-08-25T16:52:00.000-07:00

FRISCO, Texas, Aug. 11, 2008 (PRIME NEWSWIRE) -- John Pentony, Publisher of Stockguru.com, announced today that the company has posted a new Podcast Interview featuring Charles A. Fust, Founding Chairman and CEO of SinoFresh Healthcare (OTC BB:SFSH.OB - News). SinoFresh HealthCare is a developer and marketer of innovative, patented upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh(tm) Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh(tm) products are available online at www.sinofreshstore.com.

To listen to the StockGuru.com interview with Charles A. Fust of SinoFresh Healthcare, please visit:

http://www.stockguru.com/index.php?id=67 (Copy and paste link into Web Browser)

SinoFresh Nasal Spray Kills MRSA 'Super-Bug' in Live Noses

2008-08-19T19:19:00.000-07:00

VENICE, Fla., Aug. 19 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc., (OTC Bulletin Board: SFSH - News) announced preliminary results today from a successful in vivo pilot study indicating that its patented SinoFresh® nasal spray was shown to be useful in controlling the MRSA "super-bug" in the nasal passages. This study utilized a recognized scientific model intended to demonstrate SinoFresh® nasal spray's ability to kill MRSA hiding in the nasal passages. These favorable efficacy results follow an earlier, successful in vitro study that was conducted at the Public Health Research Institute under the direction of Dr. Barry Kreiswirth, director of the Tuberculosis Center and Hospital Infections Program.

The study showed that "SinoFresh® nasal spray used three times daily appeared to effectively eliminate MRSA in the noses of the test animals while leaving enough normal microbes to keep a normal population in the nasal passages," according to Dr. John Todhunter, consultant to SinoFresh, who oversaw the study conducted at Virion Systems in Rockville, MD.

MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is a growing concern in the health care community. It incubates in the nasal passages and then gets on the skin where it can cause severe, virulent infections. The effect of MRSA can lead to disfigurement and sometimes death. MRSA is also highly antibiotic resistant, making MRSA infections difficult to treat. It is believed that approximately 2 - 3 million persons in the U.S. walk around carrying MRSA in their nasal passages at any time and elimination or severe reduction of nasal MRSA colonies is seen as a potentially important weapon in fighting the spread of MSRA. The antibiotic Mupirocin is currently used to reduce nasal MRSA loads.

SinoFresh® nasal spray attacks MRSA in the nasal passages by destroying the "super-bug's" cell walls and membranes by physical means rather than by an antibiotic mechanism involving attack on the metabolism of the microbes as occurs with the use of antibiotics. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics the chances for development of resistance to SinoFresh® Nasal Spray's mode of killing them is much lower said Dr. Todhunter."

According to William Wilferth, VP for Research and Development at SinoFresh, "These results have exceeded our expectations. The positive results of this in vivo study gives us the solid scientific platform we have needed in order to advance our efforts to fight MRSA to the next level."

Charles Fust, CEO of SinoFresh, noted that the data reported is extremely encouraging and that there is a significant market need for new methods to address MRSA control which is believed to be as many as 80 to 100 million treatments annually in the United States alone.

Click to buy sinofresh products from its own store
www.sinofreshstore.com.

SINOFRESH TO STUDY ANTIBACTERIAL BENEFITS OF NASAL CLEANSING SPRAY IN HORSES

2008-07-31T01:06:00.000-07:00

SinoFresh HealthCare, Inc. today announced that it will embark on a program to study the ability of its nasal spray, SinoFresh™ Nasal Mist, to protect horses against colonization with methicillin resistant Staphylococcus aureus (MRSA) bacteria. Scott Weese, DVM, of the Department of Clinical Studies at the, Ontario Veterinary College, University of Guelph, will direct the studies in collaboration with SinoFresh. These studies follow positive results of previously reported in vitro experiments showing efficacy against MRSA.

MRSA derives its name from its resistance to common antibiotics. It is a major concern for human infection in hospitals and long-term care facilities where elderly and immunocompromised patients are especially susceptible. MRSA is also a critical issue with veterinarians and animal breeders where overuse of antibiotics can lead to disease. MRSA colonization frequently occurs in the mucous membranes of the nose.

“MRSA has emerged as an important problem in animals, particularly horses and dogs. Our main concerns are the potential for animals to develop serious diseases, and the possibility of animal-to-human transmission,” explained Dr. Weese. “We’re excited to work with SinoFresh, and the potential of its nasal spray to address MRSA in animals without facilitating further resistance.”

“With concern over antibiotic resistant Staphylococcus aureus rising among researchers worldwide, we are encouraged by this higher level of scientific evaluation,” stated Charles Fust, Chairman and CEO of SinoFresh. “We have long held the notion that our innovative research efforts, spanning more than eight years, hold great promise in this particular arena.” Click to know more on MRSA

Visit Sinofreshstore

SinoFresh Announces Next Step in Program to Attack Super-Bug MRSA

2008-07-29T23:10:00.000-07:00

VENICE, FL-- On the heels of the recent announcement stating a commitment to develop a product to attack MRSA -- the so-called "super bug," SinoFresh HealthCare, Inc. (OTC BB:SFSH.OB - News) announced today the continuation of a series of development activities to implement that commitment. This is a study, which will be in the lab phase by the end of July 2008, and according to Dr. John Todhunter, an outside consultant to SinoFresh, "is expected to give robust proof of concept for the nasal formulation designed to kill MRSA hiding in the nose."

The SinoFresh formulation evolves from a well-established antimicrobial agent which is classed by FDA as "generally recognized as safe and effective" and has been used in other applications for a number of years. The present study follows an in vitro study conducted at Public Health Research Institute under the direction of Dr. Barry Kreiswirth who heads the institute's Tuberculosis Center and Hospital Infections Program, and will be an in vivo study using a well validated model reflecting demonstrated results relative to MRSA colonizing in the human nose. "Efficacy has been proven in a 'test tube' and now we're moving to show MRSA killing properties in a living nose," said Dr. Todhunter, President of SRS International.

MRSA (which stands for methicillin resistant Staphylococcus aureus) is a growing concern in the health care community. It hides in the nasal passages and then gets on the skin where it can cause severe, virulent infections which can lead to disfigurement and sometimes death. It is also highly antibiotic resistant which makes MRSA infections difficult to treat.

According to Dr. Todhunter there is an apparent consensus in the health care community that having a high nasal load of MRSA is associated with increased rates of MRSA infection. Eradication of nasal MRSA colonies is seen as a potentially important weapon in reducing the spread of MRSA. The antibiotic Mupirocin is currently the treatment of choice for reducing nasal MRSA loads. It has become less effective as MRSA resistance to it has emerged. SinoFresh's approach to killing MRSA in the nasal passages is based on the potent ability of the SinoFresh active ingredient as an antimicrobial which destroys bacterial cell walls and membranes. This happens by physical means rather than by an effect on bacterial metabolism which is how antibiotics work. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics, the chances for development of resistance to SinoFresh's nasal formulation is much lower," said Dr. Todhunter.

According to William Wilferth, VP for Research and Development at SinoFresh, "We stated earlier we were going to be very aggressive in the pursuit of MRSA solutions. Our commitment in launching this most recent in vivo study moves us further down that path." Charles Fust, CEO of SinoFresh HealthCare, Inc., stated, "I remain cautiously optimistic in light of published statements on the topic of MRSA, exampled by, the average incremental cost per patient with an acquired infection is $15,275 multiplied by at least 2,000,000 infections indicating possible cost to hospitals of $30.5B, [Clinical Infectious Diseases (v. 36, 2003) 1424-1432], suggests a potentially rewarding market receptive to new alternatives."

Visit Sinofreshstore